# OnCo record pharos (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/pharos/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "pharos", "NCT03915951" ;
  schema:name "PHAROS"@en ;
  schema:description "PHAROS showed that the melanoma combination encorafenib and binimetinib shrinks three quarters of untreated BRAF V600E lung cancers and nearly half of previously treated ones, giving a second approved BRAF plus MEK pair for lung cancer."@en ;
  schema:url <https://onco.cc/trials/pharos/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03915951>, <https://doi.org/10.1200/JCO.23.00774> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/braf-v600e-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/encorafenib/>, <https://onco.cc/drugs/binimetinib/>, <https://onco.cc/drugs/dabrafenib-trametinib/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/braf-v600-mutation/> .